Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 46.30 -1.13% -0.53
AGIO closed down 1.13 percent on Wednesday, October 30, 2024, on 80 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: Oct 31
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
Overbought Stochastic Strength -1.13%
Up 3 Days in a Row Strength -1.13%
Up 4 Days in a Row Strength -1.13%
Pocket Pivot Bullish Swing Setup 0.48%
Stochastic Reached Overbought Strength 0.48%
Gapped Up Strength 0.48%
Overbought Stochastic Strength 0.48%
Up 3 Days in a Row Strength 0.48%
Overbought Stochastic Strength 2.68%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 13 hours ago
Down 1% about 13 hours ago
Possible NR7 about 14 hours ago
Rose Above Previous Day's High about 17 hours ago
60 Minute Opening Range Breakout about 17 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Agios Pharmaceuticals, Inc. Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Hydrogen Metabolism Organic Chemistry Glutamate Inborn Errors Of Metabolism Pyruvate Kinase Deficiency

Is AGIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 53.285
52 Week Low 20.4
Average Volume 471,219
200-Day Moving Average 37.68
50-Day Moving Average 44.70
20-Day Moving Average 43.49
10-Day Moving Average 45.44
Average True Range 1.64
RSI (14) 58.51
ADX 13.76
+DI 24.86
-DI 16.93
Chandelier Exit (Long, 3 ATRs) 42.28
Chandelier Exit (Short, 3 ATRs) 44.87
Upper Bollinger Bands 47.78
Lower Bollinger Band 39.19
Percent B (%b) 0.83
BandWidth 19.75
MACD Line 0.55
MACD Signal Line 0.12
MACD Histogram 0.4369
Fundamentals Value
Market Cap 2.59 Billion
Num Shares 55.9 Million
EPS -3.94
Price-to-Earnings (P/E) Ratio -11.75
Price-to-Sales 58.47
Price-to-Book 1.58
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 48.02
Resistance 3 (R3) 48.13 47.67 47.74
Resistance 2 (R2) 47.67 47.23 47.62 47.64
Resistance 1 (R1) 46.99 46.96 46.76 46.87 47.54
Pivot Point 46.52 46.52 46.41 46.47 46.52
Support 1 (S1) 45.84 46.09 45.61 45.73 45.06
Support 2 (S2) 45.38 45.81 45.32 44.96
Support 3 (S3) 44.69 45.38 44.86
Support 4 (S4) 44.58